New mRNA vaccine aims to shield adults from RSV
NCT ID NCT07289503
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage trial tests a new mRNA vaccine (ABO1105) against respiratory syncytial virus (RSV) in 96 healthy adults aged 18 and older. The main goal is to check the vaccine's safety and how well the body's immune system responds. Participants receive one injection at one of three dose levels or a placebo, and are monitored for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baise Center For Disease Control & Prevention
Baise City, Baise, China
Conditions
Explore the condition pages connected to this study.